It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
There is an unmet need for new influenza vaccine strategies that compensate for impaired vaccine responses in elderly individuals. Here, we evaluated the effectiveness of a single-stranded RNA (ssRNA) as an adjuvant to enhance the efficacy of inactivated influenza vaccine (IIV) in mouse models. Immunization with the ssRNA along with IIV reduced viral titers as well as pathological and inflammatory scores in the lungs after influenza challenge in aged mice. ssRNA induced balanced Th1/Th2 responses with an increase in IgA titers. Moreover, the ssRNA adjuvant markedly increased the frequency of influenza HA-specific T cells and IFN-γ production along with the expression of genes related to innate and adaptive immune systems that could overcome immunosenescence in aged mice. Our findings indicate that ssRNA is an efficient vaccine adjuvant that boosts cellular and humoral immunity in aged mice, demonstrating its potential as a novel adjuvant for currently available influenza virus vaccines for elderly individuals.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 The Catholic University of Korea, Department of Medical and Biological Sciences, Bucheon, Republic of Korea (GRID:grid.411947.e) (ISNI:0000 0004 0470 4224); The Catholic University of Korea, BK Plus Department of Biotechnology, Bucheon, Republic of Korea (GRID:grid.411947.e) (ISNI:0000 0004 0470 4224)
2 The Catholic University of Korea, Department of Medical and Biological Sciences, Bucheon, Republic of Korea (GRID:grid.411947.e) (ISNI:0000 0004 0470 4224)
3 SK Bioscience, Department of R&D, Bundang-gu, Republic of Korea (GRID:grid.411947.e)
4 Scripps Korea Antibody Institute, Chuncheon, Republic of Korea (GRID:grid.482586.5)
5 SK Bioscience, Department of R&D, Bundang-gu, Republic of Korea (GRID:grid.482586.5)
6 Ewha Womans University, Graduate School of Pharmaceutical Sciences, Seoul, Republic of Korea (GRID:grid.255649.9) (ISNI:0000 0001 2171 7754)
7 Korea University, Department of Microbiology, College of Medicine, Seoul, Republic of Korea (GRID:grid.222754.4) (ISNI:0000 0001 0840 2678)